Pharma/Biotech Deal Strategy & Implementation from Lexington, Mass.

What Apo does:

ApoConsult assists pharma/biotech clients with transforming corporate collaborations, including planning, execution, and implementation. These new corporate deals (and the deal process itself) rapidly take the client to the next competitive level.

How Apo executes:
1) Systematic development of partnering strategy;
2) Positioning client's key deal assets for optimal presentation;
3) Senior-level access to potential partners, leveraging extensive global contact network; and
4) Assistance through the negotiations to the signed deal and beyond.

Consultant's background:
Jim Feeney (JPF) has over 25 years of experience in international business development including:

• Consultant, late 2003-present, to boards, CEO's, and busdev VP's at leading bigpharma and biotech, biopharma, and bioscience (diagnostics/biomarker platform) firms on partnering deals. Areas of potential-partner focus include senior pharma/biotech management in R&D, oncology, inflammation, translational medicine, personalized medicine, and related biomarker analysis.
  
• Head of Business Development, 1993-2003, at 3 leading biopharmaceutical firms: Vertex, heading 6-person expert team; CytoMed (now UCB and Millennium, respectively); and Mitotix (now GPC Biotech), with completed deals valued in the hundreds of millions ($).
  
• Firm-wide Partner and also Founder/President of Tokyo office (subsidiary), 1981-1991, for leading Europe-based management consulting firm SiAR-Bossard (now Capgemini). Global business experience includes 8 years based in Tokyo; also based in Paris and Stockholm.
  
• MBA, in Strategic Management and Finance, taken mid-career at the Wharton School (Univ. of Pennsylvania), 1991-1993; and AB from Harvard University.
  
• Member of the following organizations: BIO; Massachusetts Biotechnology Council (MBC); Licensing Executives Society (LES); New York Academy of Sciences (NYAS); and New York Pharma Forum (NYPF).
  
• Foreign languages: Japanese, Russian, French, Spanish, and Finnish.